Inmaculada Fernández

Inmaculada Fernández

Auto-generated profile, based on publicly available information

Inmaculada Fernández

Aparato Digestivo, Hospital Universitario 12 de Octubre

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
JCJavier Crespo
Javier Crespo
JCJose Luis Calleja
Jose Luis Calleja
IFInmaculada Fernández
Inmaculada Fernández
BSBegoña Sacristan
Begoña Sacristan
BRBELEN RUIZ-ANTORÁN
BELEN RUIZ-ANTORÁN
GSGloria Sánchez-Antolín
Gloria Sánchez-Antolín

1 May 2017 in Transplantation
Verified
Journal Article
Closed access
CFCarlos Fernández-Carrillo
Carlos Fernández-Carrillo
GCGonzalo Crespo
Gonzalo Crespo
JRJuan de la Revilla
Juan de la Revilla
LCLluís Castells
Lluís Castells
MBMaria Buti
Maria Buti
MLMaria Carlota Londono
Maria Carlota Londono
Background Guidelines recommend that patients with hepatitis C virus (HCV)-related liver disease be treated for HCV before liver transplant (LT) to eliminate the virus before surgery. However, the unpredictability of donor organ availability may limit treatment duration. Interruption of HCV treatment with resumption post-LT is 1 potential solution which has not been investigated widely. Methods Patients from 5 clinical centers included in the large, national, noninterventional Hepa-C registry who started treatment with direct-acting antiviral agents while awaiting LT were identified retrospectively and followed up prospectively. Fifteen patients who had treatment interruptions around LT were identified. Results The majority of patients (12/15) received interferon-free regimens, most commonly sofosbuvir + daclatasvir (8/12), for a total of 24 weeks (13/15). Treatment was discontinued temporarily for a median of 5 (range, 2-33) days. Fourteen patients completing 12 weeks of follow-up achieved a sustained virological response. One patient who died before week 12 posttreatment achieved a response at posttreatment week 4. Treatment was generally well tolerated. Serious adverse events were recorded in 2 of 15 patients (anaemia in 1 patient; pneumonia in 1 patient); all arose after LT. Conclusions Resumption of direct-acting antiviral agent therapy after a temporary interruption around LT was highly effective, achieving sustained virological response in all patients who completed 12 weeks of posttreatment follow-up. Treatment was generally well tolerated pretransplantation and posttransplantation, with a low rate of serious adverse events. Such a strategy may offer an important new approach to the treatment of patients awaiting LT which may be assessed in future studies.

1 January 2022 in Revista Española de Enfermedades Digestivas
Verified
Journal Article
Open access
AFAna Suárez-Saro Fernández
Ana Suárez-Saro Fernández
FSFlor María Fernández-Gordón Sánchez
Flor María Fernández-Gordón Sánchez
CCCarolina Muñoz Codoceo
Carolina Muñoz Codoceo
ÁRÁlvaro Hidalgo Romero
Álvaro Hidalgo Romero
IVInmaculada Fernández Vázquez
Inmaculada Fernández Vázquez
We present the case of a 64-year-old male with a history of chronic liver disease due to hepatitis C virus, with a sustained viral response after oral antiviral treatment and without follow-up for 5 years. He was admitted after a one-month history of constitutional symptoms, low-grade fever, abdominal pain and a palpable epigastric tumor. Analysis showed marked elevation of acute phase reactants (48,000 leukocytes and C-reactive protein of 19mg/dl) and dissociated cholestasis. Two lesions were identified by abdominal CT.